Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2020-06-09 Capital/Financing Update
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent genomför framgångsrikt en riktad emission av aktier om cirka 487 MSEK (cirka 47 MEUR)
Capital/Financing Update Classification · 98% confidence The document is explicitly titled a "PRESSMEDDELANDE" (Press Release) dated June 9, 2020, announcing that BioInvent has successfully completed a directed share issue (a financing activity) raising approximately 487 MSEK. It details the share price, participating investors, the structure involving two tranches (one requiring shareholder approval via an EGM), and plans for a subsequent rights issue. This content directly relates to fundraising, capital structure changes, and the issuance of new shares. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it involves share issuance (SHA) and a future EGM (which might relate to DVA/PSI), the primary focus and purpose of this announcement is the capital raise itself.
2020-06-09 Swedish
BioInvent successfully completes a directed share issue of approximately SEK 487 million (approximately EUR 47 million)
Capital/Financing Update Classification · 99% confidence The document is explicitly titled as a "PRESS RELEASE" dated June 9, 2020, announcing that BioInvent successfully completed a "directed share issue of approximately SEK 487 million." The content details the issuance of new shares, the price, the participating investors, the resulting dilution, and plans for a subsequent rights issue. This activity directly relates to fundraising, financing activities, and changes in capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the financing event itself.
2020-06-09 English
Beslut på BioInvents årsstämma 2020
AGM Information Classification · 98% confidence The document is explicitly titled "Beslut på BioInvents årsstämma 2020" (Decisions at BioInvent's Annual General Meeting 2020) and details the outcomes of the meeting, including board elections, approval of financial statements for 2019, decisions on dividends, remuneration guidelines, and authorization for future share issuance. These topics are central to an Annual General Meeting (AGM). Since the document reports the *decisions* made at the meeting rather than being a proxy statement or a voting result announcement, the most appropriate classification is AGM Information (AGM-R). It is not a full 10-K, an earnings release (ER), or a proxy statement (PSI).
2020-05-28 Swedish
Resolutions at BioInvent’s Annual General Meeting 2020
AGM Information Classification · 99% confidence The document is explicitly titled 'Resolutions at BioInvent's Annual General Meeting 2020' and details the outcomes of the AGM, including the election of board members, approval of financial statements, and decisions on remuneration and share authorization. This content directly corresponds to the definition of AGM Information.
2020-05-28 English
Notice to Annual General Meeting in BioInvent International AB
AGM Information Classification · 99% confidence The document is explicitly titled "Notice to Annual General Meeting in BioInvent International AB". It details the date, time, location, procedures for attendance (including postal voting due to COVID-19), and presents the full agenda for the meeting. The agenda items cover standard AGM topics like election of the Chairman, approval of financial statements (Item 8), appropriation of results (Item 9), election of the Board and Auditor (Items 10-13), remuneration guidelines (Item 14), and amendments to the Articles of Association (Item 15). This content is the core material for soliciting shareholder votes and providing necessary information ahead of the AGM, which aligns perfectly with the definition of AGM Information (AGM-R). It is not a proxy statement (PSI) which typically solicits votes via a proxy card, nor is it the Annual Report (10-K) itself, although it references the Annual Report for context on Item 8.
2020-04-28 English
Kallelse till årsstämma i BioInvent International AB
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i BioInvent International AB" which translates to "Notice of Annual General Meeting in BioInvent International AB". It details the date, time, location, procedures for participation (including registration deadlines and proxy rules), and the proposed agenda items for the meeting. Key agenda items include the presentation of the annual report (item 8), decisions on financial results and dividend (item 9), election of the board and auditor (items 10-13), and decisions on remuneration guidelines and amendments to the articles of association (items 14-15). This content is characteristic of a formal notice calling shareholders to the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2020-04-28 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.